NuPathé wins FDA nod for migraine skin patch

In a bid to win FDA approval for its migraine skin patch, NuPathé, a pharmaceutical company, has undergone several revisions to the patch to ensure its safety and efficacy. The company has worked closely with regulatory bodies to address concerns related to skin reactions and has made adjustments to the patch's design to improve its safety profile.

The FDA's decision to approve the patch is significant for NuPathé, as it is the first skin patch approved for the treatment of migraines. The patch is designed to deliver sumatriptan, the most-prescribed migraine headache medication via mild electrical current, through a mild electrical current.

Pathe's chief executive officer expressed his satisfaction with the FDA's decision, saying that while it was effective, the regulatory body had questions about the patch's safety, Anido said. The company has since made adjustments to the patch's design to address these concerns.

The FDA's approval of the patch is expected to provide a new treatment option for patients suffering from migraines. The patch will be available for sale in the United States, and NuPathé anticipates the product to be on the market in the fourth quarter.

The FDA's decision to approve the patch is a significant milestone for NuPathé, which has invested heavily in research and development to bring this innovative treatment to market. The company has been working closely with regulatory bodies to ensure the patch's safety and efficacy, and its approval is a testament to the company's commitment to innovation and excellence in the pharmaceutical industry.

This approval is also expected to have positive implications for the migraine treatment market, as it opens up new opportunities for patients suffering from this neurological disorder.